The Full
Spectrum

The active compound, salvinorin A, is the only κ-opioid receptor (KOR) agonist known to occur in nature. That's a different machine entirely from the classic psychedelics, which work on serotonin. Because of it, salvia shows no cross-tolerance with other psychedelics and produces something that doesn't really resemble anything else. It's active at around 200 micrograms, which makes it the most potent naturally occurring psychedelic by weight.

The κ-opioid receptor has a hand in pain, dissociation, mood, and perception. Activate it in animals and you get dysphoria and dissociation. In humans at full doses, salvinorin A tends to take reality apart and reassemble it wrong, usually without the emotional warmth the classic psychedelics bring.

Salvia divinorum grows wild in the Sierra Mazateca of Oaxaca, Mexico. The curandera María Sabina and other Mazatec healers treated it as a lesser sacrament than the mushrooms, used mainly for divination and for healing when a full mushroom ceremony wasn't the right call. Taken as fresh leaves or leaf tea, it gives a mild, divinatory state, nothing like the overwhelming hit of smoked concentrated extract.

Gordon Wasson and Albert Hofmann came across it in Mazatec communities in 1962, and Hofmann later isolated salvinorin A as the active compound, closing the loop on a career that ran from lysergic to κ-opioid chemistry.

The κ-opioid system turns up in depression, addiction, and pain, which makes salvinorin A both a useful research tool and a possible therapeutic lead. Non-psychedelic KOR agonists that stay out of the brain are being developed as peripheral painkillers, while brain-penetrating KOR modulators are being looked at for depression that won't respond to anything else. Its odd pharmacology has made salvinorin A one of the more heavily studied compounds in neuropharmacology today.

Kratom's split personality comes down to its alkaloid mix. At low doses mitragynine, the main alkaloid, acts as an adrenergic agonist: stimulation, focus, a lift in mood. Push the dose up and both mitragynine and its strong metabolite 7-hydroxymitragynine start behaving as partial μ-opioid agonists, bringing pain relief, sedation, and euphoria. 7-OH is the potent one, roughly 13 times stronger than morphine at the μ-opioid receptor by weight.

The interesting part: kratom's alkaloids look like "biased agonists." They hit the μ-opioid receptor's G-protein pathway, the one that gives you analgesia, while doing comparatively little at the β-arrestin pathway, the one behind respiratory depression and constipation. That's the exact trick drug companies have been chasing for a "safer opioid," and kratom may have stumbled onto it on its own.

Thousands of people say they've used kratom to taper themselves off opioids, handling withdrawal without ever entering a formal program. Surveys find that a good share of kratom users are former opioid users, and plenty of them credit it with keeping them alive. The literature hasn't documented a confirmed kratom-only overdose death, though mixing it with other depressants raises the risk sharply.

The DEA moved to emergency-schedule it as Schedule I in 2016, then backed off after a public-comment campaign few had seen the likes of, with more than 23,000 comments against. The plant sits in a legal gray zone to this day, with the FDA still taking action against adulterated products.

Blue lotus (Nymphaea caerulea) shows up in Egyptian art in ways that point to ritual use going back at least to 1350 BCE. It was in Tutankhamun's tomb, in scenes from the Book of the Dead, carved into the pillars at Karnak. The flowers were steeped in wine for ceremony, which paired the lotus alkaloids with alcohol's loosening effect.

Egyptologist Lyn Green and archaeobotanist David Sherrat have laid out the case for blue lotus as an ancient entheogen, used in funerary rites, fertility ceremonies, and sanctioned states of altered consciousness. The flower, rising out of the mud to open above the water each morning, became a natural metaphor for resurrection and divine awakening.

The main actors are nuciferine, an aporphine alkaloid that behaves as a partial dopamine D2 agonist with antipsychotic properties, and nornuciferine. They touch the dopamine and serotonin systems in ways nobody has fully mapped. By modern standards the effects are mild: a little euphoria, some relaxation, faintly brighter visuals, more vivid dreams. And there's the aphrodisiac reputation that's followed it for thousands of years.

Combination with wine (as used historically) may enhance effects through alcohol-mediated disinhibition and altered metabolism.

Kava's effects come from its 18 kavalactones, kavain, dihydrokavain, methysticin, and dihydromethysticin chief among them. They work on several fronts at once: blocking voltage-gated sodium channels (muscle relaxation and pain relief), boosting GABA-A activity (the calm), and nudging dopamine pathways (the mild lift). Unlike benzodiazepines, kavalactones don't seem to build tolerance or dependence under traditional use.

In randomized trials, kavain eases anxiety at 150–400mg a day, roughly on par with benzodiazepines but without the cognitive dulling, the sedation, or the dependence.

A 2013 double-blind trial in the Journal of Clinical Psychopharmacology found kava extract beating placebo on generalized anxiety, with the effect showing up around week two and holding by week four. It was well tolerated, left cognition alone, and, unlike SSRIs and benzodiazepines, leaned toward improving sexual function rather than wrecking it.

In Fiji, Vanuatu, Samoa, Tonga, and Hawai'i, the kava ceremony is the social institution, about what wine is to the Mediterranean, except it's drunk communally from a shared bowl as part of bonding, settling disputes, and making decisions. Chiefs, elders, and everyone else pass the bowl to seal agreements and mark the big transitions. And the kava bar is steadily taking the alcohol bar's place across the Pacific, and increasingly in US cities too.

San Pedro (Echinopsis pachanoi) carries mescaline as its main psychoactive alkaloid, around 0.12% of fresh weight, plus more than fifteen other phenethylamine and isoquinoline alkaloids: tyramine, hordenine, anhalidine, and the rest. That fuller mix is thought to be why the San Pedro experience reads so differently from pure mescaline, softer, warmer, more bodily.

The cactus grows from Ecuador down through Peru along the Andean cordillera, and finds at the Chavín de Huántar temple complex push its use back to at least 1400 BCE. The Spanish called it San Pedro, after Saint Peter, keeper of the gates of heaven, and the Christian name probably did more than anything to shield it from being stamped out in the colonial years.

Led by a curandero working with the brew called "wachuma," the San Pedro ceremony is a twelve-hour healing ritual built around naming an illness, physical or emotional or spiritual, and working it loose. People keep calling the experience "grandfatherly": warm and grounded and embodied next to the more visionary, otherworldly feel of ayahuasca. A strong pull toward the natural world, the earth, and ancestral lineage runs through most accounts.

As the ceremony gets revived in modern healing settings, it's generating a fresh pool of observational data on trauma, depression, and chronic pain, much like the ayahuasca literature but with a noticeably different feel to the experiences described.

Peganum harmala seeds hold harmine, harmaline, and tetrahydroharmine (THH), β-carboline alkaloids that reversibly inhibit monoamine oxidase, MAO-A in particular. By shutting down the enzyme that would otherwise break DMT apart in the gut and liver, these harmala alkaloids make orally taken DMT active. That's the whole mechanism behind ayahuasca, and the realization that the ayahuasca vine pulls the same pharmacological trick as Syrian rue.

Persian, Middle Eastern, and Central Asian traditions came to rue on their own, using it as an antidepressant, a dewormer, and a visionary medicine. TiHKAL notes that harmaline and harmine are mildly psychoactive in their own right, enough for a gentle visionary state alone, well before the MAOI activity turns dangerous in the wrong combination.

Harmine and harmaline have their own plasticity story too. Harmine strongly inhibits DYRK1A, a kinase tied to neurogenesis, and several studies have shown it pushing human neural progenitor cells to multiply in vitro, which hints at a neurogenic effect quite apart from the MAOI one. That makes it a research candidate in its own right for depression, Alzheimer's, and other neurodegenerative conditions.

THC's mechanism is a strange one: it acts on a receptor system the body already runs for its own purposes. That endocannabinoid system has CB1 receptors, packed into the brain (prefrontal cortex, hippocampus, basal ganglia, cerebellum), and CB2 receptors, mostly out in immune tissue. The body's own ligands for it, anandamide and 2-AG, are close cousins of THC. The whole system helps regulate pain, appetite, memory, immune function, and mood.

THC binds CB1 tightly, especially in the prefrontal cortex and basal ganglia, which is why it does what it does to thought, perception, and movement. Why it hits people so differently comes down to how much their CB1 expression and endocannabinoid tone vary from one person to the next.

The FDA has already approved cannabis-derived drugs: dronabinol (synthetic THC, sold as Marinol) for chemo nausea and AIDS wasting, nabilone for the same, and Epidiolex (CBD) for certain childhood epilepsies. The clinical evidence is strongest for neuropathic pain, chemotherapy-induced nausea, and MS spasticity, where the systematic-review data actually holds up.

Newer work is looking at cannabis in PTSD (several veterans' studies show symptoms easing), inflammatory bowel disease, and as a helper in opioid tapering. Some of the more interesting results are about CBD on its own, particularly what it does at TRP channels, GPR55, and the 5-HT₁A receptor.

Thrown into the mix, cannabis can amplify and bend a psychedelic experience quite a bit. CB1 activation plays off the 5-HT₂A effects, often deepening the visuals and turning up the psychological intensity. On its own at high doses it can get psychedelic in its own right: mild depersonalization, visual oddities, a deep introspective pull. Combining it with other psychedelics is a coin toss worth thinking about, since it can just as easily rescue a hard trip or blow it wide open.

CBD's pharmacology is strikingly complex for a "non-psychoactive" compound. Unlike THC, CBD has very low affinity for CB1 and CB2 receptors — it works primarily through: 5-HT₁A receptor agonism (explaining anxiolytic and antidepressant effects); TRPV1 and TRPA1 channel modulation (explaining anticonvulsant and anti-inflammatory properties); GPR55 inverse agonism; inhibition of adenosine reuptake (contributing to anti-inflammatory effects); and weak GABA-A potentiation.

It also acts as a negative allosteric modulator at CB1 receptors — meaning it reduces the effect of THC when present, explaining why high-CBD cannabis strains are less anxiety-provoking than high-THC strains.

The FDA's 2018 approval of Epidiolex (pharmaceutical-grade CBD) for Dravet syndrome and Lennox-Gastaut syndrome was a real turning point, the first time a plant-derived cannabinoid had cleared the agency. The pivotal trials showed seizures dropping by roughly 40% against 14–17% on placebo. After decades of Schedule I prohibition, it put cannabis on the books as legitimate medicine.

Emerging evidence supports CBD in anxiety disorders (particularly social anxiety disorder, where several RCTs show significant efficacy), psychosis (as an adjunct in schizophrenia — a paradoxical finding given THC's psychosis risk), and as an opioid-sparing analgesic. The PTSD research combining CBD with psychotherapy is particularly active and promising.

5-MeO-DMT is the methoxy cousin of N,N-DMT, and that one extra oxygen atom changes everything: instead of a crowded visionary journey you get a complete, featureless dissolution of the self. It occurs in the venom of Bufo alvarius, the Sonoran Desert toad, and in plants like Anadenanthera peregrina, which South American cultures have ground into ceremonial snuffs for thousands of years.

Pharmacologically, it is a potent agonist at 5-HT₂A and 5-HT₁A receptors, with particularly high affinity for 5-HT₁A — which may account for the stark qualitative difference from DMT. The Sigma-1 receptor activation provides neuroprotective and neuroplastic effects similar to its close relative.

Where N,N-DMT gives you geometric entities and crowded landscapes, 5-MeO-DMT delivers what Stanislav Grof called "unitive consciousness," subject and object collapsing into one. Most people report no visuals at all. What's left is bare, undivided awareness, described in the same breath as empty void and as overwhelming presence. The first moments are usually frightening, and surrender is the only thing that works. Plenty come back out the other side with the deepest sense of love and peace they've ever felt.

Onset at smoked doses is near-instantaneous. The experience is often described as "too much, too fast, too real" — significantly more intense than N,N-DMT despite the shorter chemical distance. Integration takes considerable time; the experience can be disorienting for days.

A 2019 study in Frontiers in Psychiatry followed 5-MeO-DMT taken in ceremonial settings and found fast, lasting drops in anxiety and depression that were still holding at the four-week check-in. The 2024 Stanford veterans study often pairs 5-MeO-DMT with ibogaine in its MISTIC protocol, the one where every one of the 30 combat veterans responded on the PTSD measure.

The PTSD research is especially busy right now. The proposed mechanism is a quick burst of 5-HT₁A activation that "resets" the fear-conditioned circuits in the amygdala, in effect a biological reprieve from the constant hypervigilance that defines PTSD.

4-AcO-DMT (O-acetylpsilocin) was first synthesized by Albert Hofmann and Franz Troxler in 1963 — just a few years after Hofmann's isolation of psilocybin. It is the acetyl ester of psilocin, and is widely believed to act primarily as a prodrug — rapidly deacetylated to psilocin in the body by plasma esterases. This would make it pharmacologically nearly identical to psilocybin itself, though at slightly different potency ratios.

Whether it also has activity in its native form remains pharmacologically unsettled — some subjective reports suggest a slightly "smoother" quality than psilocybin, which may reflect metabolic differences or direct receptor activity.

People who've taken it tend to say 4-AcO-DMT is all but indistinguishable from psilocybin mushrooms: warm, organic visuals with real emotional weight, deep introspection, stretches of genuine compassion for yourself and others, and a rich afterglow. The synthetic form lets you dose precisely in a way mushrooms never allow. Push the dose and full ego dissolution and mystical-type experiences show up about as often as they do with psilocybin.

Reports frequently describe a softer, more forgiving character compared to LSD — more likely to produce emotional catharsis than analytical insight, more likely to generate wonder than paranoia. Often associated with deep appreciation of music, art, and natural environments.

Because 4-AcO-DMT is believed to convert to psilocin, it theoretically carries all the therapeutic potential of psilocybin — neuroplasticity via BDNF, 5-HT₂A agonism, ego dissolution-mediated psychological flexibility. It has not been studied independently in clinical trials, but its similarity to psilocybin makes it an interesting research chemical for laboratories seeking to study psilocin pharmacokinetics.

DET (N,N-diethyltryptamine) was studied extensively by Shulgin and documented in TiHKAL. Its two ethyl groups in place of DMT's two methyl groups produce a molecule that is orally active — a striking property given DMT's complete oral inactivity without MAOIs. The mechanism of oral activity isn't fully characterized but may relate to differential MAO substrate specificity.

It was one of the earliest tryptamines clinically studied, appearing in mid-20th century psychiatric literature under the designation T-9. Early researchers were struck by its unusual combination of psychedelic and empathogenic properties.

Shulgin collected reports across multiple routes and doses. At 75mg orally: "Onset seemed to be at 40 minutes — an absolutely profound, enriching experience." At 40mg smoked: users described immediate camaraderie, heightened tactile sensitivity, and spontaneous purring with companions. At 60mg IM by early researchers: "The yellow walls had an air of medieval mood about them. A painter's eye was awakened — looking at things with an unusual conscious attention."

Across reports, DET is consistently described as more social and empathogenic than DMT — less likely to produce entity contact or reality dissolution, more likely to open emotional warmth and connection. The visual element is present but secondary to the interpersonal quality.

DET was part of a wave of tryptamine research in Eastern Europe in the 1950s and 60s. Hungarian researchers studied it in schizophrenic patients and healthy volunteers, producing detailed phenomenological reports. This research was largely lost to Western science during the Cold War, only recovered through Shulgin's archival work in TiHKAL.

4-HO-MET is a member of the 4-hydroxy tryptamine family — the same chemical class as psilocin (4-HO-DMT). The substitution of one methyl group for an ethyl group on the nitrogen produces a compound with a notably different experiential character despite similar receptor binding. It is synthesized by reacting indole with methyl ethyl oxalyl chloride and reducing the resulting amide.

Like all 4-hydroxy tryptamines, 4-HO-MET is a direct 5-HT₂A agonist — it does not require metabolic conversion and produces effects more rapidly than psilocybin. The precise pharmacological reason for its characteristically visual and euphoric character (compared to psilocybin's more introspective tendency) remains unexplained — possibly due to differential 5-HT₂C or 5-HT₁A activity.

4-HO-MET is consistently described as one of the most visually spectacular tryptamines — producing vivid, richly colored, rapidly shifting geometric patterns that many users find more aesthetically satisfying than psilocybin. The emotional content is lighter and more playful than the heavy introspective quality often associated with mushrooms. It is frequently described as "euphoric" and "fun" — an unusual word in the tryptamine vocabulary — without sacrificing depth at higher doses.

Music gets a huge lift. The body feel is generally pleasant, without the nausea mushrooms can bring, and the afterglow is mild and positive.

Bufotenine (5-hydroxy-DMT) is the 5-hydroxy analog of DMT — with the hydroxyl group at the 5-position instead of DMT's absent substitution or 5-MeO-DMT's methoxy. It occurs naturally in Anadenanthera peregrina (yopo/cohoba beans) — sacred to numerous South American indigenous cultures — in Bufo alvarius toad venom, and is produced endogenously in the human body. TiHKAL documents its role as the primary alkaloid in yopo beans alongside DMT and 5-MeO-DMT.

It was long dismissed by Western science as a peripheral vasoconstrictor with no psychedelic activity — a classification based on flawed early studies using peripheral administration routes. More careful research has established genuine psychedelic activity when bufotenine reaches the brain.

Contemporary reports describe a short, powerful experience with vivid chromatic hallucinations, floods of deep purple, green, and gold, plus a strong physical component including cardiovascular stimulation. At lower doses, users report visual enhancement and mood elevation reminiscent of DMT but more "earthy." At breakthrough doses, the experience shares features with DMT but with a distinctive quality often described as "ancient" or "ancestral."

The yopo ceremony — which includes bufotenine-rich seeds blown into the nasal passage through ceremonial pipes — has been practiced for at least 4,000 years in South America. The contemporary revival of this ceremony in healing contexts is producing observational data on its therapeutic potential.

AL-LAD (6-allyl-6-nor-LSD) is entry #1 in TiHKAL, synthesized from nor-LSD by N-allylation with allyl bromide. Shulgin documented the synthesis in characteristic detail, noting a yield of 88% as white crystalline product with mp 88–90°C. It is an LSD analog in which the two N-diethyl substituents of LSD are replaced by a 6-allyl and 6-nor substitution pattern — producing a compound with broadly similar but distinctly different pharmacology.

At doses of 80–160 micrograms (similar to LSD dosing), AL-LAD produces effects lasting 6–8 hours — roughly half the duration of LSD. The shorter window and characteristically lighter, more visual, and more playful nature compared to LSD have made it popular in the research chemical community.

Reports consistently characterize AL-LAD as more visual and less introspective than LSD — producing colorful, playful, beautiful visuals with a lighter psychological weight. The emotional content is more uniformly positive and euphoric; the likelihood of difficult psychological content is reduced compared to LSD. Music enhancement is pronounced. Many describe it as the "gentle" version of the LSD experience — suitable for nature environments and creative work.

The shorter duration (6–8 hours versus LSD's 10–14) is frequently mentioned as a practical advantage for users who find LSD's length difficult to accommodate.

DiPT (N,N-diisopropyltryptamine) is TiHKAL #4 — and arguably the most scientifically intriguing entry in the entire book. Where DMT, psilocin, and 5-MeO-DMT primarily transform vision and sense of self, DiPT does something no other known psychedelic does at this magnitude: it rewrites the auditory cortex. Voices drop in pitch. Music becomes harmonically disharmonious. Familiar instruments sound foreign. Mind and body remain remarkably clear — the trip is happening in the ears.

Shulgin's reports document the phenomenology in technicolor: at 18mg, "Wild effects noted in an hour. Remarkable changes in sounds heard. My wife's voice is basso, as if she had a cold... Radio voices are all low, music out of key. Piano sounds like a bar-room disaster. The telephone ringing sounds partly underwater." At 50mg orally: "Everything was auditory, and I can only describe it with a '!'" At 250mg, one tester recorded children's voices sounding like aliens speaking through synthesizers — a complete restructuring of harmonic perception while retaining cognitive lucidity.

A physician colleague of Shulgin's framed the puzzle in neurological terms: "If the drug delayed only the neural response to a stimulus, then pitch might have been shifted down, and yet harmony between notes should have been preserved. A variable delay related to the pitch of the stimulus would produce the disharmony but would not explain the preservation of normal relationship between single tones." DiPT, in other words, isn't simply slowing or shifting auditory processing — it's selectively scrambling pitch and harmonic relationships in ways that don't fit any single existing model of audition.

Shulgin himself proposed using a carbon-11-labeled analog with PET imaging to localize the affected brain regions — observing that DiPT might be a uniquely powerful tool for mapping the pitch-processing centers of the auditory cortex. "Here is a drug that goes directly after the hearing system, rather than the seeing system," he wrote. "This could well be a tool for two things. First, the localization of the pitch center in the brain. And second, it is a prototypic drug that might allow structural modification in several directions."

Most users describe DiPT as a uniquely strange but cognitively clean experience — none of the visual cathedral-building of DMT, none of the emotional opening of psilocin, just a profound rewriting of how sound is perceived. Conversations become surreal. Music becomes nearly unlistenable for many. Some testers describe the alteration as enchanting and creatively useful (composers exploring how their pieces would sound at different harmonic relationships); others find it disorienting and unpleasant. Body load is generally low.

Shulgin and his English collaborator Michael Carter co-developed 5-MeO-DiPT in the late 1970s, publishing the first chemistry and pharmacology in 1981. The 5-methoxy substitution combined with two bulky isopropyl groups on the nitrogen produces a tryptamine that is orally active at unusually low doses (6–12mg), atypical among the simpler N,N-substituted tryptamines, most of which require parenteral routes or much higher oral doses.

Pharmacologically, 5-MeO-DiPT is a 5-HT₂A and 5-HT₁A agonist with significant affinity for 5-HT₂C and a profile distinct from its parent compound DiPT. Shulgin observed that the auditory distortions characteristic of DiPT survive into 5-MeO-DiPT but with a different quality — affecting "musical character and interpretation" rather than raw harmonic structure.

Across user reports gathered in TiHKAL, the erotic quality is the most consistently reported feature. One subject at 7mg: "In one hour I was in a marvelous, sexy place. Everything was shaded with eroticism. Sex was explosive... As a short term aphrodisiac, this leaves 2C-B in the dust." Another at 12mg described preparation with candles, pillows, and a partner: "Warm led into a wonderful sexual turn on, where my entire body was alive and alert."

The compound's quality is body-and-sensation focused rather than visually or cognitively transformative — Shulgin noted some users found it lacking in the intuitive or insight-generating qualities typical of psychedelics. Visual phenomena are minimal at moderate doses; emotional and physical sensitivity is the main signal.

DPT (N,N-dipropyltryptamine) — TiHKAL entry #9 — occupies a unique position in psychedelic history as the only tryptamine to be successfully integrated into a recognized contemporary religious community. The Temple of the True Inner Light, founded in New York City, embraced DPT as their primary sacrament, smoking or drinking it during communion. The Temple has, remarkably, operated without significant federal interference for decades — a rare regulatory exception that Shulgin himself reflected on with a sort of bemused wonder.

User reports during religious use frequently describe encounters with luminous beings, tunnels of light, and visions strikingly similar to near-death and mystical-experience phenomenology. One subject at 250mg: "I was seeing the Light real strongly. The Light sort of looked like bright bursts of Light but also like a kind of Spiritual Tunnel... the Vision seemed like I was sort of inside the Being and outside, and the Human was inside me."

DPT has one of the most substantial clinical research histories of any TiHKAL tryptamine. In the 1970s, William Richards and colleagues at the Maryland Psychiatric Research Center used DPT (15–30mg IM as low-dose, 75–125mg IM as peak-experience dose) in two major contexts: first, as an adjunct to alcoholism treatment, where its capacity to enhance recall, emotional expression, and self-exploration produced therapeutic results; and second — most poignantly — as an adjunct to psychotherapy for cancer patients facing end-of-life, where peak mystical experiences produced significant reductions in death anxiety and existential distress.

The short duration (2–4 hours) compared to LSD or psilocybin made DPT particularly suited to clinical contexts. The end-of-life work in particular foreshadowed the contemporary psilocybin research at Johns Hopkins and NYU by 40 years.

DPT smoked produces an experience compared by users to DMT but distinctly its own — visions of geometric architecture, encounters with non-human intelligences, and overwhelming light experiences. At oral doses of 100–250mg, the experience extends to 2–4 hours with rich visual and spiritual content. The "religious" character — encounters described as encounters with God, Christ, ancestral figures, or impersonal divine presence — is reported with unusual frequency, even among non-religious users.

4-HO-MiPT (4-hydroxy-N-methyl-N-isopropyltryptamine) is TiHKAL #22 — a psilocin analog in which one of psilocin's two methyl groups has been replaced with an isopropyl group. The asymmetric N-substitution pattern (one methyl, one isopropyl) is a recurring Shulgin theme — he repeatedly observed that asymmetric substitution often produces the most refined experiential profiles among related compounds. 4-HO-MiPT is among the strongest data points for that hypothesis.

Like psilocin and other 4-hydroxy tryptamines, 4-HO-MiPT is a direct 5-HT₂A agonist not requiring metabolic activation — onset is faster than psilocybin, and effects are typically more "clean" with less of the body-load and stomach discomfort sometimes associated with mushrooms.

User reports consistently describe 4-HO-MiPT as one of the most user-friendly tryptamines outside of mushrooms themselves — clean, bright, visually rich, emotionally warm, with a graceful body feel and minimal afterglow fatigue. The experience is often called a "best of both worlds" combination: the warmth of psilocybin combined with the visual clarity of 4-HO-MET and the social ease of MiPT. Music enhancement is significant; tactile sensitivity is enhanced without the heavy emotional intensity of MDMA.

The 4–6 hour duration places it in the practical sweet spot between short-acting tryptamines and the all-evening commitment of mushrooms. Many users describe it as their preferred research chemical for both solo introspective work and small social gatherings.

MiPT (N-methyl-N-isopropyltryptamine) is TiHKAL #47, an asymmetrically N-substituted tryptamine that Shulgin noted as "mixed, complex" in the 10–25mg oral range. The single methyl group on one nitrogen and isopropyl group on the other produces a compound subtly different in character from its symmetric cousins — less visual than DiPT or DMT, less emotional than psilocin, but with a distinct cognitive openness.

Shulgin's broader work with the methyl-isopropyl pattern across both 4-hydroxy and 5-methoxy tryptamines (4-HO-MiPT, 5-MeO-MiPT) suggested this asymmetric substitution recurrently produces compounds with refined, accessible, and orally-active profiles.

Unlike most tryptamines, MiPT users consistently report cognitive clarity — the ability to read, write, hold complex conversations, and think analytically while experiencing the subtle alterations of the compound. Visual phenomena are present but understated: pattern enhancement, mild flow states, color saturation. Body load is generally light. Emotional content is gentle rather than overwhelming.

For users seeking a tryptamine that supports rather than disrupts thinking — for creative work, philosophical exploration, or deep conversation — MiPT occupies an unusual niche. It's been compared to a "thinking dose" of psilocybin minus the body load and visual distraction.

ETH-LAD (6-ethyl-6-nor-LSD) is entry #12 in TiHKAL — synthesized from nor-LSD by N-ethylation. Where AL-LAD has an allyl group at the 6-position and PRO-LAD has a propyl group, ETH-LAD has an ethyl group — and the qualitative difference between the three lysergamide variants is dramatic. Shulgin documented all three in TiHKAL alongside LSD itself, and the experiential reports from his testing circle reveal striking distinctions in character despite similar underlying pharmacology.

ETH-LAD is approximately equipotent to LSD, sometimes slightly more potent — active at 40–150 micrograms. Its 5-HT₂A binding affinity is high; its 5-HT₂C and 5-HT₁A profile differs subtly enough to produce a qualitatively distinct experience.

User reports characterize ETH-LAD as the "deepest" of the major lysergamide analogs — more emotionally weighty than AL-LAD, more visionary than LSD, with a particular tendency toward introspection and personal psychological work. Visuals are generally described as more flowing and organic than LSD's geometric character. The compound has been noted for producing exceptionally rich closed-eye visuals and a strong sense of meaning and significance throughout the experience.

Body load is variable — some users report moderate nausea in the first hour, particularly at higher doses. The 8–12 hour duration is shorter than LSD's typical 10–14 hours, making it slightly more practical, though still a full-day commitment.

2C-B was synthesized by Alexander Shulgin in 1974 and became his personal favorite among his hundreds of compounds. Documented in PiHKAL as entry #20, he described it as "perhaps the most ideal psychedelic" — noting its remarkable dose-sensitivity, clean pharmacology, and the extraordinary integration of sensory and empathogenic qualities. The bromo substitution at the 4-position of the mescaline-related 2,5-dimethoxyphenethylamine scaffold produces a potent but controllable compound.

It binds with high affinity to 5-HT₂A and 5-HT₂C receptors, with additional activity at dopaminergic systems explaining its stimulant-adjacent character. It has uniquely steep dose-response — 12mg produces mild effects, 20mg produces full psychedelia. The two-milligram difference in the middle of that range is experientially significant.

2C-B throws off gorgeous visuals, richly colored and organic and flowing, alongside an MDMA-ish emotional opening and a real sharpening of the senses. Touch becomes something else. Music turns almost architecturally visible. That blend of full-on visual psychedelia and heightened sensuality is something no other major psychedelic quite matches.

Shulgin's PiHKAL reports from the compound's early testing circle describe it consistently as warm, gentle, and erotic at lower doses; fully psychedelic at higher. The "body load" is minimal compared to many phenethylamines. The 4–6 hour window is considered a feature — enough depth without the exhausting length of LSD or mescaline.

Before its scheduling in the US in 1995, 2C-B was used therapeutically by a network of psychedelic therapists as an alternative and adjunct to MDMA — particularly for couples therapy and sexual trauma work, where its combination of empathy and sensory enhancement was considered uniquely suited. Underground therapeutic use continues in global harm reduction contexts.

PiHKAL #29 documents 2C-E (4-ethyl-2,5-dimethoxyphenethylamine), with Shulgin rating it among the most significant compounds in the phenethylamine series. The ethyl substitution in place of 2C-B's bromine produces a compound of greater depth and demanding character. Shulgin's own report at 16mg described the experience as difficult to yield to — producing "a constant urge to be doing something" alongside intense visual phenomena.

2C-E shows potent 5-HT₂A agonism. Its extended duration (8–12 hours) sets it apart from most 2C compounds and contributes to its reputation as one of the most challenging phenethylamines.

2C-E is consistently described as one of the most visually stunning and intellectually demanding psychedelics. Where 2C-B produces warmth, 2C-E produces a cool, crystalline intensity — more LSD-like in its analytical, architectural character. The visuals are extraordinarily detailed and geometric. The introspection is deep and sometimes uncomfortable. Many experienced psychedelic users rate it among their most significant experiences; many beginners find it overwhelming.

DOM (4-methyl-2,5-dimethoxyamphetamine) was synthesized by Alexander Shulgin and documented in PiHKAL as compound #68. At the 1967 San Francisco Summer of Love, large quantities were distributed as "STP" — a name Shulgin later learned stood for "Serenity, Tranquility, Peace." The tablets were massively overdosed at 10mg+, producing experiences lasting up to 30 hours. The attempt to treat overwhelmed users with chlorpromazine (Thorazine) dramatically worsened outcomes — a seminal harm reduction lesson that still reverberates.

DOM contains both the 2,5-dimethoxy phenethylamine scaffold and an amphetamine-type methyl group — making it a potent 5-HT₂A agonist with significant dopaminergic stimulant properties. The combination produces the unique quality of LSD-like psychedelia with amphetamine energy, explaining the intense physicality and extreme wakefulness.

DOM's defining feature is duration. Even at threshold doses, the experience runs 12+ hours. At active doses, 20–30 hours is reported. The character is stimulating, visually intense, and analytically complex — described as more "sharp" and "mechanical" than psilocybin or mescaline. Sleep is completely impossible during the experience.

MDA predates MDMA in both synthesis (1910) and psychedelic research. It was studied in the 1960s by researchers including Gordon Alles (who synthesized amphetamine) and Claudio Naranjo, who used it in therapeutic sessions producing remarkable results in patients. MDA releases serotonin, dopamine, and norepinephrine like MDMA, but additionally shows agonist activity at 5-HT₂A receptors — adding a genuine hallucinogenic component absent from MDMA.

The result is an experience that blends MDMA's emotional opening and empathogenic quality with visual phenomena closer to a mild psilocybin experience. Some researchers consider MDA to have been the superior therapeutic agent of the two, owing to this added introspective depth.

Claudio Naranjo conducted extensive psychotherapy sessions with MDA in Chile in the 1960s–70s, treating depression, neurosis, and existential crisis. He described it as producing "a state of increased emotional accessibility" — patients reported reaching emotional material impossible to access in conventional therapy. His work represents some of the earliest rigorous psychedelic psychotherapy, predating the current clinical renaissance by decades.

TMA-2 (2,4,5-trimethoxyamphetamine) is compound #158 in PiHKAL. Shulgin found it to be approximately twice as potent as TMA (3,4,5-trimethoxyamphetamine — the amphetamine analog of mescaline) — active at 20–40mg. The 2,4,5 substitution pattern (rather than the 3,4,5 of mescaline) produces a more stimulating compound with a higher potency-to-weight ratio.

Shulgin's own reports on TMA-2 describe unusual lucidity and analytical clarity sitting alongside mescaline-style visuals, mostly heightened color and geometric patterning. The amphetamine backbone tacks on a sustained wakefulness and mental drive that mescaline itself doesn't have.

Described as mescaline with amphetamine — rich color enhancement, geometric visual phenomena, and expanded consciousness paired with unusual mental energy and wakefulness. Duration is long (8–16 hours), placing it among the more demanding phenethylamines. Shulgin noted it as producing "perhaps the finest esthetic and intellectual experience" of any compound in the TMA series.

2C-T-7 is PiHKAL entry #43 and one of the most celebrated phenethylamines Shulgin ever synthesized. In his commentary, he wrote: "If all the phenethylamines were to be ranked as to their acceptability and their intrinsic richness, 2C-T-7 would be right up there near the top, along with 2C-T-2, 2C-B, mescaline and 2C-E." This grouping — the so-called Magical Half-Dozen — represents Shulgin's personal highest-ranked compounds across decades of work.

Structurally, 2C-T-7 is a 2,5-dimethoxyphenethylamine with an n-propylthio group at the 4-position. The sulfur substitution distinguishes it from the bromine of 2C-B and the ethyl of 2C-E — and the resulting compound is significantly longer-lasting, deeper, and more visionary in character than either.

User reports collected by the Shulgins describe 2C-T-7 as producing some of the most aesthetically rich and adaptable visual phenomena in the phenethylamine family. One subject at 30mg: "The visuals have an adaptable character to them. I can use them to recreate any hallucinogenic substance I have known and loved. With open eyes, I can go easily into LSD flowing visuals, or into the warm earth world of Peyote... With closed eyes, there are Escher-like graphics with a lot of chiaroscuro, geometric patterns with oppositional play of sculptured light and dark values. Green light."

At 20mg, another tester described becoming engrossed in stillness, with music revealing "extraordinary importance" — a meditative kind of deep listening. The compound is widely associated with deep emotional and spiritual content, music appreciation, and aesthetic insight. Shulgin himself favorably compared it to 2C-T-2, eventually preferring 2C-T-7 in his personal hierarchy.

Despite its placement in the Magical Half-Dozen, 2C-T-7 is associated with several documented fatalities — primarily from insufflated overdoses, sometimes combined with MAOIs or other compounds. Erowid maintains a chronological vault of these incidents. The fatalities highlight that Shulgin's compounds, even at their most refined, demand careful dosing, route awareness, and respect for individual sensitivity.

2C-T-2 is PiHKAL entry #40 — the ethyl-thio variant in the 2C-T family that opened up the entire sulfur sub-series of phenethylamines for Shulgin. Where 2C-B substitutes a bromine atom at the 4-position of the 2,5-dimethoxyphenethylamine core, 2C-T-2 uses an ethylthio group (S-ethyl), and 2C-T-7 uses a propylthio group (S-propyl). The sulfur atom dramatically modifies the experiential character — producing deeper emotional content, extended duration, and a different quality of visual phenomena.

In Shulgin's original commentary, he placed 2C-T-2 alongside 2C-B and 2C-E among the most refined and useful compounds in his collection. While he eventually preferred 2C-T-7 in his personal hierarchy, 2C-T-2 retained its place in the Magical Half-Dozen.

2C-T-2 is widely described as having a uniquely "therapeutic" quality — producing introspective access to emotional material that other compounds may not reach as cleanly. The visual component is present but typically secondary to the emotional and somatic content. Body awareness is heightened; users frequently report being able to localize emotional content somatically (chest tightness associated with grief, throat constriction with unspoken truths) and work through these experiences during the session.

The 6–8 hour duration is more practical than 2C-T-7's 8–12 hours, making 2C-T-2 a popular choice for intentional psychotherapeutic work. The compound has been used extensively in underground therapeutic networks, particularly for couples work and trauma processing, where its combination of emotional accessibility and body-awareness fits the therapeutic frame.

2C-I (4-iodo-2,5-dimethoxyphenethylamine) is PiHKAL #33 — the iodine-substituted 2C compound. Where 2C-B uses bromine at the 4-position, 2C-I substitutes iodine, producing a compound of similar but slightly higher potency and duration. The iodine atom is significantly larger than bromine, fluorine, or chlorine, and the resulting compound has notably different binding kinetics at 5-HT₂A and 5-HT₂C receptors.

The compound has historically been less popular in underground supply chains than 2C-B due to its longer duration and somewhat more demanding character — but it has loyal users who specifically prefer its sharper, more stimulating quality and richer visual phenomena.

Users consistently describe 2C-I as more visually vivid than 2C-B, with stronger color enhancement and more pronounced geometric pattern formation. The emotional and erotic qualities of 2C-B are present but often less prominent — replaced by a more analytical, more energized character. Music enhancement is significant; tactile sensitivity is enhanced. The 6–10 hour duration is longer than 2C-B's 4–6 hours, placing it as more of a full-evening commitment.

Body load includes mild stimulation and occasional jaw tension — not extreme, but more present than with 2C-B. Many users describe 2C-I as well-suited for creative work, festivals, and contexts where they want sustained energy combined with psychedelic depth.

DOI (4-iodo-2,5-dimethoxyamphetamine) is PiHKAL #67 and arguably the single most important compound in 5-HT₂A pharmacology research. Its high binding affinity, well-characterized stereochemistry, and the availability of radioiodinated [¹²⁵I]-DOI as a binding probe have made it the gold standard for studying serotonin receptor pharmacology. Thousands of peer-reviewed papers reference DOI as the agonist of choice in receptor-binding assays, behavioral models, and neuroplasticity studies.

Recent research at UC Davis (Olson Lab) has used DOI to study psychedelic-induced neuroplasticity — particularly dendritic spine growth and BDNF release. DOI's anti-inflammatory effects at extremely low doses (1000-fold below psychedelic threshold) have generated significant pharmaceutical interest as a potential treatment for asthma and inflammatory conditions.

In PiHKAL, Shulgin grouped DOI together with DOB (the bromine analog) and DOC (the chlorine analog) as the "halo-amphetamines" — all approximately equipotent (1.5–3mg active doses) and all extraordinarily long-lasting (16–30+ hours). Shulgin's tester at 2.4mg reported still being at "a full plus three" at the sixth hour, with the experience extending well past 18 hours. Visuals are characteristically intense and detailed — flowing geometric patterns, deeply saturated color, and architectural distortion of physical space. The mental character is described as crystalline and somewhat "amphetaminic" — wakefulness combined with deep psychedelic phenomena.

Mescaline is PiHKAL #96 — and although Shulgin synthesized hundreds of phenethylamines, mescaline was the foundation of his entire research program. His first mescaline experience in the 1960s — taking 400mg of synthetic mescaline sulfate — was, in his own words, the moment that determined the rest of his life. Everything that followed (the 2C-x family, the DO-x amphetamines, TiHKAL's tryptamines) emerged from his attempt to understand and refine the experience he encountered with this original alkaloid.

Mescaline is found naturally in Lophophora williamsii (peyote, used ceremonially in Mesoamerica for 5,700+ years), Echinopsis pachanoi (San Pedro), Echinopsis peruviana (Peruvian Torch), and several other cacti. Its 3,4,5-trimethoxy substitution pattern is the structural prototype for all of Shulgin's subsequent phenethylamine work — every 2C compound, every DO compound, every TMA represents a structural permutation of mescaline's basic skeleton.

Mescaline is consistently described as qualitatively different from its synthetic descendants — warmer, more grounded, more "natural" in character. Where 2C-E is crystalline and analytical, mescaline is luminous and earthy. Where LSD is architectural and structural, mescaline is biological and organic. The visual phenomena are characteristically rich in flowing color, organic patterns, and natural beauty. The body feel is warm rather than tense; the emotional content is openhearted rather than confronting.

Aldous Huxley's The Doors of Perception (1954) set down his mescaline experience with unusual precision, watching flowers and the folds of fabric turn fully real, alive, and somehow transcendent. Huxley's account remains one of the foundational texts of psychedelic literature. Shulgin himself placed mescaline alongside 2C-B, 2C-T-2, 2C-T-7, and 2C-E in his Magical Half-Dozen — among the highest-ranked compounds in his lifetime of research.

The Native American Church uses peyote sacramentally, protected under the American Indian Religious Freedom Act (1978). The all-night ceremony involves prayer, song, and community healing — and has been associated with significant rates of recovery from alcoholism in Native American communities. The Huichol people of Mexico's Sierra Madre Occidental have an unbroken peyote tradition stretching back at least 1,500 years, with the annual Wirikuta pilgrimage representing one of the world's longest-continuously-practiced religious ceremonies involving a psychedelic plant.

GANESHA is PiHKAL #85 — Shulgin chose the name deliberately, evoking the Hindu deity associated with removing obstacles and granting wisdom. He characterized the compound as an "insight-enhancer" in his commentary, describing how at 24mg orally it produced a state of "increased emotional accessibility" without the visual overwhelm typical of higher doses or shorter-acting compounds. The therapeutic potential of this quality, combined with its long duration, made GANESHA particularly suited for inner work and psychological exploration.

Structurally, GANESHA is the 3,4-dimethyl analog in the DO-x amphetamine family — placing it alongside DOM (4-methyl) and adjacent compounds in the substitution-pattern landscape. It was the first phenethylamine Shulgin found to be approximately equipotent with its corresponding amphetamine — challenging his earlier assumption that phenethylamines were systematically weaker than amphetamines.

Tester reports collected by the Shulgins describe GANESHA at 32mg as producing extended access to deep emotional and psychological material — without the visual intensity of LSD or the body load of DOM. The energy character is described as "tremor" or "buzzy" — present throughout the experience, sometimes mildly uncomfortable, but tolerable. The very long duration (14–20+ hours) makes the compound impractical for most recreational contexts but well-suited for sustained psychotherapeutic sessions where extended emotional access is the goal.

ALEPH-2 is PiHKAL #4 — part of Shulgin's "ALEPH" series of sulfur-containing amphetamines. (The original ALEPH, the methylthio compound, opened the sub-series; ALEPH-2 substitutes ethylthio.) The ALEPH compounds were Shulgin's earliest work with sulfur-containing phenethylamine analogs, predating his more famous 2C-T series. The shift from amphetamine to phenethylamine backbone in the 2C-T series came after extensive work with the ALEPHs revealed the high inter-individual variability characteristic of these sulfur compounds.

The name "ALEPH" is deliberate — the Hebrew letter Aleph represents primacy, the beginning, the silent letter that contains all sound. Shulgin chose it to honor the foundational role these compounds played in opening up the sulfur-containing chemical space.

ALEPH-2 is consistently described as producing a deeply therapeutic and psychologically accessible experience — comparable in some respects to 2C-T-2 but with the amphetamine backbone adding a different energy quality. Visual phenomena are present but secondary to the emotional and somatic content. Body awareness is heightened; emotional material rises with unusual clarity. The compound has been used in underground therapeutic contexts for inner work, particularly trauma processing and relational repair.

The high potency (4–8mg active doses) makes precise dosing critical. Inter-individual variability is significant — what is a moderate experience for one person may be overwhelming for another. Shulgin specifically commented on this variability as a defining feature of the ALEPH series.

Nitrous oxide was first synthesized by Joseph Priestley in 1772 and popularized by Humphry Davy, who noted its extraordinary psychological effects in 1800 — writing that "Nothing exists but thoughts." William James, the father of American psychology, wrote extensively on his nitrous oxide experiences as producing genuine insight into the nature of consciousness. It remains the most widely used psychoactive substance after alcohol, caffeine, and tobacco.

Its mechanism involves NMDA glutamate receptor antagonism (shared with ketamine) and κ-opioid receptor agonism — producing dissociation, analgesia, and euphoria. It is still widely used in medical anesthesia and dentistry worldwide.

At mild doses: laughter, warmth, mild dissociation, and auditory distortion producing characteristic "wa-wa-wa" sound. At higher doses: complete dissociation, ego dissolution, and perception loops — moments of consciousness repeating fractally, often with a sense of having accessed a fundamental truth. The brevity means these moments are experienced as crystalline flashes rather than developed journeys.

William James described his nitrous experiences as providing the most convincing evidence he had ever encountered that "our normal waking consciousness is but one special type of consciousness, whilst all about it, parted from it by the filmiest of screens, there lie potential forms of consciousness entirely different."

Recent research has demonstrated nitrous oxide's rapid antidepressant properties — similar in mechanism to ketamine. A 2021 study in Science Translational Medicine found that a single one-hour nitrous oxide session produced significant antidepressant effects lasting two weeks in treatment-resistant depression patients. It is now being investigated as a cheaper, more accessible alternative to ketamine infusion therapy.

DXM's effects are uniquely categorized into "plateaus" based on dose: First plateau (100–200mg) — mild stimulation and psychedelia. Second plateau (200–400mg) — significant dissociation, visual disturbances, euphoria. Third plateau (400–700mg) — heavy dissociation, possible out-of-body experiences. Fourth plateau (700mg+) — complete dissociation, profound and potentially dangerous.

DXM is a Sigma-1 receptor agonist, NMDA antagonist, and serotonin reuptake inhibitor — a uniquely complex pharmacological profile. Its active metabolite dextrorphan is the primary NMDA-active species. Sigma-1 agonism produces the distinctive dissociative quality that differs subtly from ketamine.

DXM combined with quinidine (which inhibits DXM metabolism) is FDA-approved as Nuedexta for pseudobulbar affect. The combination is now being studied for major depressive disorder, with Phase 2 trials showing antidepressant effects comparable to ketamine but at far lower cost. The Sigma-1 activation may contribute independently to antidepressant and neuroprotective effects.

PCP (phencyclidine) was developed by Parke-Davis in the 1950s as Sernyl — a surgical anesthetic that produced complete anesthesia without respiratory depression. It was abandoned for medical use due to severe emergence delirium in patients recovering from anesthesia — producing agitation, confusion, and hallucinations. The subsequent development of ketamine by Calvin Stevens in 1962 was a direct response to PCP's problematic profile, with the goal of creating a shorter-acting, less severe alternative.

PCP's scientific contribution was enormous — it was through PCP and ketamine research that the NMDA glutamate receptor was identified as a key substrate of anesthesia, analgesia, and consciousness. Every modern understanding of glutamate's role in depression, psychosis, and consciousness traces directly to PCP research.

PCP produces profound analgesia — the inability to feel pain — combined with complete dissociation from reality. The combination can produce extremely dangerous behavior due to the absence of normal pain feedback and severely distorted perception. At low doses, users describe stimulation and mild euphoria; at medium doses, significant dissociation and perceptual distortion; at high doses, complete detachment from reality with amnesia. The analgesia is so profound that users have been documented sustaining severe injuries without awareness.

Datura's effects are produced by a shifting mixture of three tropane alkaloids — atropine, scopolamine (also called hyoscine), and hyoscyamine. All three are competitive antagonists at muscarinic acetylcholine receptors — blocking the cholinergic signaling that underlies both peripheral autonomic function (heart rate, salivation, digestion, pupil dilation, sweating) and central cognitive function (memory, attention, perception). The classical toxidrome is summarized by the mnemonic: "blind as a bat, mad as a hatter, red as a beet, hot as a hare, dry as a bone, the bowel and bladder lose their tone, the heart runs alone."

Atropine (dl-hyoscyamine) is the prototype — longer-acting, more peripherally active, produces the pronounced tachycardia and dilation. It is still used in medicine as an antidote for organophosphate poisoning and as a pre-anesthetic. Scopolamine is more centrally active, more sedating, and produces the characteristic profound anterograde amnesia — patients have no memory of events during the drug's peak. It is used medically for motion sickness (Transderm-Scop patches). Hyoscyamine is the levorotatory isomer of atropine and behaves similarly but with slightly different tissue distribution.

Critically, the alkaloid ratio varies enormously — between species, between plants of the same species, between parts of the same plant, between seasons, between years, even between seeds on the same seedpod. This variability is the single most dangerous feature of datura. A dose that produced an uncomfortable experience in one preparation can be lethal in the next.

Unlike psychedelics, which distort perception but generally preserve the user's sense that the distortions are produced by a drug, deliriants produce hallucinations that are perceptually indistinguishable from reality. The classic datura report involves extended conversations with phantom people — friends, family members, strangers who are not present — that the user has no idea are hallucinations at the time. Users have been documented going to work, holding conversations with co-workers who are not there, picking up objects that do not exist, smoking phantom cigarettes, and having no awareness anything is unusual.

The amnesia is near-total. People come away with fragmentary, dreamlike, or no memory of it at all. Reports are reconstructed from eyewitness accounts and the aftermath. Most reports describe the experience — retrospectively — as terrifying, confusing, physically miserable, and deeply unpleasant. Experienced psychedelic users who have tried datura overwhelmingly report they will never repeat it.

The physical toxidrome is severe and prolonged. Heart rate can exceed 150 bpm for hours. Body temperature can rise to dangerous levels (hyperthermia is a common cause of death). Inability to urinate, severe mouth dryness, blurred vision lasting days, and photophobia are standard. Peak effects last 8–12 hours; residual effects, pupil dilation, and cognitive impairment can persist 2–3 days.

Datura species appear in the ethnobotanical records of virtually every culture that encountered them — across the Americas, Europe, Asia, and Africa. But unlike ayahuasca, peyote, or mushrooms, datura is almost never described as a celebrated sacrament. It appears instead as the province of specialists — shamans, witches, sorcerers — who used it rarely, with great caution, and who warned the uninitiated in the strongest possible terms. European witch-trial records describe the "flying ointment" — datura and belladonna rendered into fat and applied to mucous membranes — used by specialists who knew the doses.

Several Indigenous North American nations used datura (the species Datura wrightii and Datura inoxia) in coming-of-age ceremonies — administered by elders in carefully measured preparations, within highly structured ritual containers, with days of recovery supervised by the community. These contexts bear no resemblance to contemporary experimentation. The fatalities and permanent psychiatric injuries that have occurred in modern recreational datura use are not a failure of the plant; they are the predictable result of removing a dangerous specialist's tool from the context that made it survivable.

Atropa belladonna contains the same tropane alkaloid mixture as datura — predominantly atropine and hyoscyamine, with variable scopolamine. The effects and risks are essentially identical to datura. Its cultural history is European rather than American: the plant takes its name from the Italian bella donna ("beautiful lady"), referring to the Renaissance practice of using dilute belladonna drops to dilate women's pupils — considered an attractive feature. The genus name Atropa comes from Atropos, the Fate who cuts the thread of life.

Belladonna was the primary ingredient in European witches' flying ointments — lard-based preparations applied to mucous membranes to bypass the nauseating effects of oral consumption and deliver the alkaloids through transdermal absorption. Confessions from the witch trials describe vivid sensations of flight, meetings with otherworldly figures, and bacchanalian revels. Modern readings treat these as the predictable content of anticholinergic delirium rather than evidence of witchcraft.

Brugmansia species are widely cultivated as ornamental trees — their large, pendulous, trumpet-shaped flowers are spectacular, and they grow easily in warm climates. They are popular in gardens from California to the Mediterranean, often planted by homeowners with no awareness of their toxicity. Every part of the plant contains tropane alkaloids in quantities sufficient to cause anticholinergic delirium, and poisonings from children and curious adults are documented annually.

Traditional use in the Andes involves small amounts added to ayahuasca brews by some shamans — a practice considered specialist-only and quite different from the primarily harmaline/DMT ayahuasca of the Amazon. It is also used topically in some folk-medicine contexts. The scopolamine-dominant alkaloid profile tends to produce more pronounced sedation and amnesia than atropine-dominant datura.